In the first, each participant was asked what minimum average increase in survival would justify the inclusion of a hypothetical new treatment for cancer within the Spanish health system, considering that the new drug presented a cost difference of 50.000 euros with respect to the reference treatment. . The results showed that, in all cases, the suggested limits are above those usually used as a reference. Oncologists and patients were the groups that were willing to pay the highest amount for the innovation achieved (106.000 euros/QALY and 73.520 euros/QALY respectively).
In the second scenario, subjects included in the study had to indicate how much they would be willing to pay for a new treatment that produced an improvement in quality of life without any advantage in terms of survival. In this case, it was the patients and the general population that generated higher values (83.000 euros/QALY and 76.000 euros/QALY respectively), highlighting the fact that patients were willing to pay a greater amount for the gains as life with respect to survival.
Luis Lizán, Director of Outcomes'10, states that "all groups are willing to pay more for improvements in cancer treatment compared to what the values currently used in our environment tell us, so this should be taken into account. that current decisions based on conventionally accepted limits may not reflect society's willingness to pay for certain health gains."
